Microdosing is typically taken once weekly
Freedman DS, Butte NF, Taveras EM, Goodman AB, Ogden CL, Blanck HM
So we're building a deep, broad portfolio of innovation and quite a number of those can actually leverage the same footprint. Additional reporting from Katie Jennings
The FLOW trial demonstrated meaningful reductions in kidney disease progression with semaglutide. The SELECT trial showed a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease. These are not trivial findings
PT-141 is studied as a melanocortin receptor research peptide in models involving neuroendocrine signaling, central nervous system regulation, behavioral pathway research, vascular signaling, and peptide receptor activation